Drug intelligence / Profile preview

Yangke powder

Development stage: Preclinical
Modality: Small Molecules

Overview

Yangke powder (yǎng ké sǎn-YKS) is a Traditional Chinese Medicine (TCM) formula that has demonstrated potential in alleviating asthma symptoms and reducing its acute exacerbation. It works by inhibiting the PI3K/AKT/NF-κB signaling pathway, which leads to improved airway resistance, reduced inflammation, decreased mucus production, and attenuated airway remodeling. The formula also reduces Th2 cytokines and IgE levels. Key active ingredients identified in Yangke powder include Kaempferol, Norephedrine, Cynaroside, Genistein, and Rutin, which impact biomarkers such as AKT1, TNF, and IL1B.

Other names: yǎng ké sǎn

Targets

IL1B (Interleukin-1 beta)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)

Beyond the preview

Go deeper on Yangke powder.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yangke powder.

Explore the full profile